1-(4-fluoro-phenyl)-5-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-4-isopropyl-1H-pyrazole-3-carboxylic acid benzyl-methyl-amide | 887703-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluoro-phenyl)-5-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-4-isopropyl-1H-pyrazole-3-carboxylic acid benzyl-methyl-amide
• 英文别名: N-benzyl-1-(4-fluorophenyl)-5-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N-methyl-4-propan-2-ylpyrazole-3-carboxamide
• CAS: 887703-69-7
• 化学式: C₂₈H₃₂FN₃O₄
• 分子量: 493.578
• InChiKey: BPIRSVMXIQENLS-DHIUTWEWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS
  申请人：Choi Chulho

  公开号：US20090170852A1

  公开（公告）日：2009-07-02

  Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.

  本文描述了一种新型化合物和制药组合物，可用作降低胆固醇和脂质的药物。更具体地说，本文描述了一种酶3-羟基-3-甲基戊二酰辅酶A还原酶（“HMG CoA还原酶”）的有效抑制剂。本文还描述了使用这些化合物和组合物治疗患有高脂血症、高胆固醇血症、高三酰甘油血症、动脉粥样硬化、阿尔茨海默病、良性前列腺增生症（BPH）、糖尿病和骨质疏松症等疾病的受试者，包括人类的方法。
• 7-(2H-PYRAZOL-3-YL)-3,5-DIHYDROXY-HEPTANOIC ACID DERIVATIVES AS HMG CO-A REDUCTASE INHIBITORS FOR THE TREATMENT OF LIPIDEMIA
  申请人：Warner-Lambert Company LLC

  公开号：EP1819681B1

  公开（公告）日：2009-08-12
• US7446121B2
  申请人：——

  公开号：US7446121B2

  公开（公告）日：2008-11-04